Fatah Kashanchi, Professor, Virology, School of Systems Biology, College of Science; Director, Laboratory of Molecular Virology, received funding for the study: “Parasite-Derived Vesicles in Babesia virulence and Vaccine Development.”
Babesia is a parasite spread by ticks. If humans contract babesiosis, they can experience influenza-like symptoms, bleeding, and organ failure. The condition is rare and affects fewer than 3,000 people in the United States per year.
Kashanchi will isolate extracellular vesicles (EVs) and utilize them to treat primary monocyte-derived macrophages (MDMs) or dendritic cells (DCs). He aims to determine inflammatory cytokine responses. Cytokines are proteins that affect the immune system.
Kashanchi and his collaborators aim to answer two research questions.
First, they want to know whether, in response to stimulation from Babesia-derived vesicles (BDVs), EVs can recruit another adapter protein, TIR domain-containing adapter inducing IFN-b (TRIF) (also known as TICAM-1).
Second, they want to know whether TRADD is also involved in the TRIF-dependent signaling pathway following B. microti and B. duncani EV entry into macrophages and dendritic cells, and if they are responsible for activating NFkB through IKKβ complex.
Kashanchi received $81,120 from Yale University on a subaward from the National Institutes of Health for this research. Funding began in Aug. 2024 and will end in late July 2025.
###
ABOUT GEORGE MASON UNIVERSITY
George Mason University is Virginia’s largest public research university. Located near Washington, D.C., Mason enrolls more than 40,000 students from 130 countries and all 50 states. Mason has grown rapidly over the past half-century and is recognized for its innovation and entrepreneurship, remarkable diversity, and commitment to accessibility. In 2023, the university launched Mason Now: Power the Possible, a one-billion-dollar comprehensive campaign to support student success, research, innovation, community, and stewardship. Learn more at gmu.edu.